Treatment of Polydrug-Using Opiate Dependents During Withdrawal
Managed detoxification is a first and necessary step prior to treatment and rehabilitation. Detoxification can be a major obstacle for some patients, and the availability of managed and safe withdrawal is a prerequisite for long-term treatment.
In our clinical practice we have felt the need for a standardised and safe detoxification treatment regimen for our opioid addicts, as dependence on multiple drugs is so common.
- To assess whether a novel standardised treatment regimen - Buprenorphine (BPN) combined with Valproate (VPA) - will result in fewer withdrawal symptoms during detoxification of opiate–polydrug users than the existing treatment regimen, i.e. Clonidine (CLN) combined with Carbamazepine (CBZ).
- To determine whether there are differences in treatment retention between the BPN/VPA and the CLN/CBZ groups.
- To assess differences in clinical side-effects and biochemical interactions between the two treatment regimens.
|Opiate Dependence Drug Dependence Substance Withdrawal Syndrome||Drug: Buprenorphine Drug: Valproate||Phase 4|
|Study Design:||Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
|Official Title:||Treatment of Polydrug-Using Opiate Dependents During Withdrawal|
Please refer to this study by its ClinicalTrials.gov identifier: NCT00367874
|Sorlandet Hospital HF, Addiction Unit (ARA)|
|Kristiansand, Vest-Agder, Norway, N-4604|
|Principal Investigator:||Oistein Kristensen, MD||Sorlandet Hospital HF, Addiction Unit|